-
Respilife is a unique system that can deliver high flows of Air or Oxygen ranging from 1 to 15 LMP.
-
Clinical studies have proved the usefulness of high flow of gases when warmed at body temperature and humidified up to 99 to 100% relative humidity and delivered through nasal cannula. Heat and Humidity prevent airway water loss, airway cooling, thickened secretions, nasal irritation & bleeding.
- Respilife allows delivery of breathing gases heated to body temperature & at nearly
100% relative humidity by nasal cannula without drying or cooling the airways, not
possible in the conventional bubble humidifiers.
- Most respiratory diseases of the neonate occur as a result of the immaturity of the
premature neonate’s lungs. The respiratory system is underdeveloped and adequate
gas exchange does not take place naturally, Thus there is a need for providing external
respiratory support.
Some of the benefits of using Bubble CPAP:
-
RESPILIFE effectively maintains Functional Residual Capacity (FRC). Most lung
diseases that lead to respiratory failure are commonly associated with a reduced FRC.
Maintaining FRC is very important to premature neonates, having a greater tendency of
airway closure when FRC falls below the closing volume.
- RESPILIFE helps reduce the infant’s Work of Breathing (WOB). There is a decrease in
infant’s minute volume and respiratory rate with RESPILIFE. Chest vibrations are caused
by the pressure oscillations from the bubbling. These pressure oscillations are
reverberated back into the infant’s airway and may provide an alternative form of gas
exchange through the principle of facilitated diffusion.
- RESPILIFE may reduce the need of intubation and mechanical ventilation. The use of
RESPILIFE avoids the need of intubation, thereby reducing the possibility of airway
injury, aspirations and secondary infection associated with the use of the ET tube. It
further reduces the need of mechanical ventilation that minimizes the possible incidence
of barotrauma.
- RESPILIFE tends to reduce the incidence of Chronic Lung Disease (CLD)
- RESPILIFE may improve the non-pulmonary outcome. Improved non-pulmonary effects
such as the tendency to increase mean weight at 36 weeks corrected gestation, increase
mean length and head circumference, reduction time to reach full oral feeds and average
length of stay.
